The drum­beat of Alzheimer’s PhI­II fail­ures con­tin­ues as vTv drug is out­per­formed by a place­bo, shares crash

The ex­ecs at vTv $VTVT have put an­oth­er nail in the cof­fin of re­cy­cled Alzheimer’s drug pro­grams.

The biotech, which float­ed an IPO on the back of an idea that it could take a failed drug from Pfiz­er and make it work based on some ret­ro­spec­tive da­ta analy­sis (sound fa­mil­iar?), re­port­ed Mon­day af­ter­noon that their lead ther­a­py azeli­ragon failed a Phase III study for mild to mod­er­ate Alzheimer’s.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.